Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (currently amended): A method of treating sepsis comprising the steps of administering to a patient with sepsis a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides ~~greater than 35%~~ about 75% or less of the total energy of the composition wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1 and wherein the composition includes a protein source and a carbohydrate source.

Claim 2 (withdrawn): A method of reducing the risk of sepsis comprising the steps of administering to a patient at risk of sepsis comprises a therapeutically effective amount of a composition, which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

Claims 3-8 (canceled)

Claim 9 (previously presented): The method of claim 1 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 10 (currently amended): A method of treating inflammatory shock comprising the step of administering to a patient suffering inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides ~~greater than 35%~~ about 75% or less of the total energy of the composition wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1 and wherein the composition includes a protein source and a carbohydrate source.

Claim 11 (previously presented): The method of claim 1 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 12 (canceled)

Claim 13 (previously presented): The method of claim 1 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

Claim 14 (previously presented): The method of claim 1 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 15 (previously presented): The method of claim 1 wherein the composition is administered enterally.

Claim 16 (withdrawn): A method for reducing the risk of inflammatory shock comprising the step of administering to a patient at risk of inflammatory shock a therapeutically effective amount of a composition which comprises at least one lipid wherein the lipid provides greater than 35% of the total energy of the composition.

Claim 17 (withdrawn): The method of claim 2 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 18 (withdrawn): The method of claim 2 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 19 (withdrawn): The method of claim 2 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 20 (withdrawn): The method of claim 2 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

Claim 21 (withdrawn): The method of claim 2 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 22 (withdrawn): The method of claim 2 wherein the composition is administered enterally.

Claims 23-28 (canceled)

Claim 29 (previously presented): The method of claim 10 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 30 (previously presented): The method of claim 10 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 31 (previously presented): The method of claim 10 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 32 (previously presented): The method of claim 10 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

Claim 33 (previously presented): The method of claim 10 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 34 (previously presented): The method of claim 10 wherein the composition is administered enterally.

Claim 35 (withdrawn): The method of claim 16 wherein the composition is in a form selected from the group consisting of medicament, functional food and nutritive product.

Claim 36 (withdrawn): The method of claim 16 wherein the composition comprises about 25% to about 70% MCT (medium chain triglycerides) by weight of total lipid and less than about 15% by weight saturated fatty acids excluding MCT.

Claim 37 (withdrawn): The method of claim 16 wherein the composition comprises a n-6/n-3 fatty acid ratio of about 2/1 to about 7/1.

Claim 38 (withdrawn): The method of claim 16 wherein the composition comprises at least one n-3 fatty acid selected from the group consisting of α-linolenic acid, EPA, DPA and DHA.

Claim 39 (withdrawn): The method of claim 16 wherein the composition comprises at least one n-6 fatty acid selected from the group consisting of linoleic acid (18:2, n-6), γ-linolenic acid (18:3, n-6), dihomo-γ-linoleninic acid (18:4, n-6) and arachidonic acid (20:4, n-6).

Claim 40 (withdrawn): The method of claim 16 wherein the composition is administered enterally.